$NKTR News
Last published 4h ago
- 4h agoNKTRNektar Therapeutics to Participate in Two Investor Conferences in NovemberPR NewswireNektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS...
- 2w agoNKTRNektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial MarketsPR NewswireSAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close
- 2w agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted
- 1mo agoNKTRAnalyst and Investor Event at EADV - NEKTAR THERAPEUTICSEarnings Call TranscriptsLadies and gentlemen, thank you for joining us and welcome to Nectar Therapeutics EADV Analyst and Investor event. After today's prepared remarks, we will host a question and answer session. If you would like to ask a qu
- 1mo agoNKTRNew Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026PR NewswireNektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD...
- 1mo agoNKTRNew Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic DermatitisPR NewswireNektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic...
- 1mo agoNKTRNektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026PR NewswireNektar Therapeutics (Nasdaq: NKTR) announced today that data from its Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata...
- 1mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of...
- 2mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of...
- 2mo agoNKTRNektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisPR NewswireNektar Therapeutics (Nasdaq: NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global,...
- 3mo agoNKTRNektar Therapeutics Q2 2026 Financial Results - NEKTAR THERAPEUTICSEarnings Call TranscriptsHello, and thank you for standing by. Welcome to the Nectar Therapeutics second quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation,
- 3mo agoNKTRNEKTAR THERAPEUTICS Q2 2026 FINANCIAL RESULTS - NEKTAR THERAPEUTICSEarnings Call TranscriptsHello, and thank you for standing by. Welcome to the Nectar Therapeutics second quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation,
- 3mo agoNKTRNektar Therapeutics Announces Second Quarter 2026 Financial ResultsPR NewswireSAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the
- 3mo agoNKTRKuehn Law Encourages Investors of Nektar Therapeutics to Contact Law FirmPR NewswireNEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ:NKTR) breached their fiduciary duties to
- 3mo agoNKTRNektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial MarketsPR NewswireNektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after ...
- 3mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors ...
- 3mo agoNKTRNektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the...
- 4mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors ...
- 5mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...
- 5mo agoNKTRNektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New YorkPR NewswireNektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global...
- 6mo agoNKTRNektar Therapeutics Q1 2026 Financial ResultsNEKTAR THERAPEUTICSEarnings Call TranscriptsHello, and thank you for standing by. Welcome to the Nectar Therapeutics first quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, t
- 6mo agoNKTRNektar Therapeutics Reports First Quarter 2026 Financial ResultsPR NewswireNektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable...
- 6mo agoNKTRThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTRPR NewswireThe Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR...
- 6mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of...
- 6mo agoNKTRNektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial MarketsPR NewswireNektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based...
- 6mo agoNKTRThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTRPR NewswireThe Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR...
- 6mo agoNKTRNektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the...
- 6mo agoNKTRNektar Therapeutics Announces Pricing of Upsized $325 Million Public OfferingPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
- 6mo agoNKTRNektar Therapeutics Announces Proposed Public OfferingPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
- 6mo agoNKTR52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with RezpegaldesleukinPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced new...
- 6mo agoNKTRNektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026PR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...
- 7mo agoNKTRData from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual MeetingPR NewswireNektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking...
- 7mo agoNKTRData from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual MeetingPR NewswireNektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia ...
- 8mo agoNKTRNektar Therapeutics Q4 2025 Financial ResultsNEKTAR THERAPEUTICSEarnings Call TranscriptsHello, and thank you for standing by. Welcome to the Nectar Therapeutics 4th Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, the
- 8mo agoNKTRNektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsPR NewswireNektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in...
- 8mo agoBSXCORTNKTRUNCYImportant Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 10, 2026 (GLOBE NEWSWIRE) -- Boston Scientific Corporation (NYSE:BSX): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Boston Scientific Corporation
- 8mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on February 20, 2026, the Organization and Compensation Committee of Nektar's Board of...
- 8mo agoNKTRNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial MarketsPR NewswireNektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, ...
- 8mo agoNKTRNektar Therapeutics to Participate in Two Investor Conferences in MarchPR NewswireNektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference...
- 8mo agoABBVQTTBHCWBNKTR+3Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsightPR NewswireRecently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia areata...
- 8mo agoNKTRNektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple SclerosisPR NewswireNektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and...
- 8mo agoAMGNCNTBNKTRAPGE+6Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsightPR NewswireRecently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis...
- 9mo agoNKTRNektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
- 9mo agoNKTRNektar Therapeutics Announces Pricing of Upsized $400 Million Public OfferingPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
- 9mo agoNKTRNektar Therapeutics Announces Proposed Public OfferingPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of...
- 9mo agoNKTRAnalyst and Investor Event to Discuss REZOLVE-AD Maintenance Data with Atopic Dermatitis ExpertsNEKTAR THERAPEUTICSEarnings Call TranscriptsLadies and gentlemen, thank you for joining us and welcome to Nectar Therapeutic Analyst and Investor event to discuss ResolveAD maintenance data with atopic dermatitis experts. After today's prepared remarks, we will ho
- 9mo agoNKTRNew REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly DosingPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced...
- 9mo agoNKTRNektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026PR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced...
- 9mo agoNKTRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of...
- 11mo agoNKTRREZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia AreataPR NewswireNektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced...